Randomized, double-blind, placebo-controlled study of the preventive effect of supplemental oral vitamin C on attenuation of development of nitrate tolerance

Department of Cardiology, KINU Medical Association Hospital, Mitsukaido, Ibaraki, Japan. wata-h@xa2.so-net.or.jp

OBJECTIVES: This study sought to evaluate the preventive effect of vitamin C, an antioxidant, on the development of nitrate tolerance. BACKGROUND: Decreased intracellular production of cyclic guanosine monophosphate (cGMP) is a mechanism of nitrate tolerance, and increased superoxide levels and reduced activation of guanylate cyclase have been observed in vitro. METHODS: In this double-blind, placebo-controlled study, 24 normal volunteers and 24 patients with ischemic heart disease (IHD) were randomized to receive either vitamin C (2 g three times daily [vitamin C group, n=12]) or placebo (placebo group, n=12). The vasodilator response to nitroglycerin was assessed with forearm plethysmography by measuring the change in FBF before and 5 min after sublingual administration of 0.3 mg of nitroglycerin. Blood samples were simultaneously obtained to measure platelet cGMP levels. FBF was measured, and blood sampling was performed serially at baseline (day 0), 3 days after administration of vitamin C or placebo (day 3) and 3 days after application of a 10-mg/24-h nitroglycerin tape concomitantly with oral vitamin C or placebo (day 6). RESULTS: There were no differences between the vitamin C and placebo groups in percent increases in FBF (%FBF) or platelet cGMP levels (%cGMP) after administration of sublingual nitroglycerin on day O (%FBF: normal volunteers 31+/-8 vs. 32+/-10; patients with IHD 32+/-9 vs. 32+/-8; %cGMP: normal volunteers 37+/-9 vs. 39+/-10; patients with IHD 38+/-10 vs. 39+/-10 [vitamin C group vs. placebo group]) or day 3 (%FBF: normal volunteers 32+/-9 vs. 33+/-9; patients with IHD 31+/-10 vs. 31+/-10; %cGMP: normal volunteers 36+/-8 vs. 37+/-9; patients with IHD 39+/-11 vs. 38+/-10 [vitamin C group vs. placebo group]). The %FBF and %cGMP in the placebo group were significantly lower on day 6 than in the vitamin C group (%FBF: normal volunteers 30+/-8 vs. 19 4, p < 0.01; patients with IHD 29+/-9 vs. 17+/-6, p < 0.01; %cGMP: normal volunteers 36 10 vs. 17+/-6, p < 0.01; patients with IHD 37+/-11 vs. 15+/-5, p < 0.01 [vitamin C group vs. placebo group]). CONCLUSIONS: These results indicate that combination therapy with vitamin C is potentially useful for preventing the development of nitrate tolerance.

This article has been cited by other articles:

				T. Csont Nitroglycerin-induced preconditioning: interaction with nitrate tolerance Am J Physiol Heart Circ Physiol, February 1, 2010; 298(2): H308 - H309. [Full Text] [PDF]

				M. V. Wenzl, M. Beretta, A. C. F. Gorren, A. Zeller, P. K. Baral, K. Gruber, M. Russwurm, D. Koesling, K. Schmidt, and B. Mayer Role of the General Base Glu-268 in Nitroglycerin Bioactivation and Superoxide Formation by Aldehyde Dehydrogenase-2 J. Biol. Chem., July 24, 2009; 284(30): 19878 - 19886. [Abstract] [Full Text] [PDF]

				G. Wolkart, M. V. Wenzl, M. Beretta, H. Stessel, K. Schmidt, and B. Mayer Vascular tolerance to nitroglycerin in ascorbate deficiency Cardiovasc Res, July 15, 2008; 79(2): 304 - 312. [Abstract] [Full Text] [PDF]

				A. Kollau, M. Beretta, A. C. F. Gorren, M. Russwurm, D. Koesling, K. Schmidt, and B. Mayer Bioactivation of Nitroglycerin by Ascorbate Mol. Pharmacol., July 1, 2007; 72(1): 191 - 196. [Abstract] [Full Text] [PDF]

				R. Parent, N. Leblanc, and M. Lavallee Nitroglycerin reduces myocardial oxygen consumption during exercise despite vascular tolerance Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1226 - H1234. [Abstract] [Full Text] [PDF]

				T. Gori, S. S. Mak, S. Kelly, and J. D. Parker Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1096 - 1101. [Abstract] [Full Text] [PDF]

				U. Jurt, T. Gori, A. Ravandi, S. Babaei, P. Zeman, and J. D. Parker Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study J. Am. Coll. Cardiol., September 1, 2001; 38(3): 854 - 859. [Abstract] [Full Text] [PDF]

				J. D. Ratz, J. J. McGuire, D. J. Anderson, and B. M. Bennett Effects of the Flavoprotein Inhibitor, Diphenyleneiodonium Sulfate, on Ex Vivo Organic Nitrate Tolerance in the Rat J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 569 - 577. [Abstract] [Full Text]

				H. Watanabe, M. Kakihana, S. Ohtsuka, and Y. Sugishita Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1194 - 1200. [Abstract] [Full Text] [PDF]

				H. Watanabe, M. Kakihana, S. Ohtsuka, and Y. Sugishita Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1201 - 1206. [Abstract] [Full Text] [PDF]

				D. Giugliano, R. Marfella, H. Watanabe, M. Kakihana, S. Ohtsuka, and Y. Sugishita Antioxidants and Nitrate Tolerance Response Circulation, September 29, 1998; 98(13): 1350 - 1353. [Full Text] [PDF]